Biologic therapy in inflammatory bowel disease

Danish Medical Journal

Volumn 60, Issue 6, 2013, Pages

  Theede, Klaus ^a   Dahlerup, Jens Frederik ^a   Fallingborg, Jan ^a   Hvas, Christian Lodberg ^a   Kjeldsen, Jens ^a   Munck, Lars Kristian ^a   Nordgaard Lassen, Inge ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BETAMETHASONE; C REACTIVE PROTEIN; CALGRANULIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN A; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PARACETAMOL; PLACEBO; PREDNISOLONE; STEROID; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ALLERGIC REACTION; ANTIBIOTIC THERAPY; ARTICLE; BIOLOGICAL THERAPY; COLON RESECTION; CROHN DISEASE; DISEASE ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; ECZEMA; ENDOSCOPY; ENTERITIS; FISTULA; HUMAN; ILEITIS; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PAIN; PNEUMONIA; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SEPSIS; SKIN INFECTION; SKIN REDNESS; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; URTICARIA; VIRUS INFECTION; INFLAMMATORY BOWEL DISEASES; SEVERITY OF ILLNESS INDEX; INFLAMMATORY BOWEL DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; SEVERITY OF ILLNESS INDEX;

EID: 84880060478     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997; 349:521-524.
2. Targan SR, Hanauer SB, Van Deventer SJ et al. A shortterm study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029-1035.
3. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;CD006893.
4. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65.
5. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130:323-333.
6. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56:1232-1239.
7. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357:228-238.
8. Sheridan C. Cimzia's setback paves way for other TNF inhibitors in Crohn's disease. Nat Biotechnol 2007; 25:487-488.
9. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007;CD006097.
10. Dignass A, Van AG, Lindsay JO et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4:28-62.
11. Travis SP, Stange EF, Lemann M et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2008; 2:24-62.
12. Louis E, Mary JY, Vernier-Massouille G et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142:63-70.
13. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105:501-523.
14. Dahlerup JF, Hvas CL, Jacobsen BA et al. Diagnostik og behandling af fistulerende Crohns sygdom. Dansk Gastroenterologisk Selskab 2011.
15. Christensen LA, Kjeldsen J, Knudsen T et al. Behandling af akut svær colitis ulcerosa. Dansk Gastroenterologisk Selskab 2011.
16. Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104:465-483.
17. D'Haens GR, Panaccione R, Higgins PD et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106:199-212.
18. Talley NJ, Abreu MT, Achkar JP et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011; 106 Suppl 1:S2-25.
19. Ford AC, Sandborn WJ, Khan KJ et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:644-59, quiz.
20. Harvey RF, Bradshaw JM. A simple index of Crohn'sdisease activity. Lancet 1980; 1:514.
21. van Assche G, Dignass AU, Reinisch W et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Journal of Crohn's and Colitis 2010; 4:7-27.
22. Stange EF, Travis SP, Vermeire S et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008; 2:1-23.
23. Belard E, Dahlerup JF, Gerstoft J et al. Retningslinjer for screening, profylakse og information før behandling med anti-TNF-alfa. Dansk Gastroenterologisk Selskab 2011.
24. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-1395.
25. Mackey AC, Green L, Liang LC et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44:265-267.
26. van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362-368.
27. Mowat C, Cole A, Windsor A et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60:571-607.
28. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
29. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885.
30. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008;CD006893.
31. Colombel JF, Schwartz DA, Sandborn WJ et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58:940-948.
32. Biancone L, Michetti P, Travis S et al. European evidence-based Consensus on the management of ulcerative colitis: Special situations. J Crohns Colitis 2008; 2:63-92.
33. Reinisch W, Van AG, Befrits R et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis 2012; 6:248-258.
34. van Assche G, Dignass AU, Reinisch W et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. Journal of Crohn's and Colitis 2010; 4:63-101.
35. Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009; 92:61-77.
36. Rahier JF, Ben-Horin S, Chowers Y et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009; 3:47-91.
37. Cheifetz A, Smedley M, Martin S et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98:1315-1324.
38. Miehsler W, Novacek G, Wenzl H et al. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis 2010; 4:221-256.
39. Breynaert C, Ferrante M, Fidder H et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 2011; 106:778-785.
40. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm Bowel Dis 2009; 15:1264-1275.
41. Fidder H, Schnitzler F, Ferrante M et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58:501-508.
42. Shmidt E, Wetter DA, Ferguson SB et al. Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-alpha inhibitors: The Mayo Clinic experience, 1998 to 2010. J Am Acad Dermatol 2011.
43. Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut 2009; 58:1033-1039.
44. Rahier JF, Buche S, Peyrin-Biroulet L et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010; 8:1048-1055.
45. Cullen G, Kroshinsky D, Cheifetz AS et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther 2011; 34:1318-1327.
46. MacDonald JK, McDonald JW. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2007;CD006097.
47. Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect 2011; 17:1776-1780.
48. Sany J, Kaiser MJ, Jorgensen C et al. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64:1647-1649.
49. Farrell RJ, Alsahli M, Jeen YT et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124:917-924.
50. Wasserman MJ, Weber DA, Guthrie JA et al. Infusionrelated reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol 2004; 31:1912-1917.
51. Lecluse LL, Piskin G, Mekkes JR et al. Review and expert opinion on prevention and treatment of infliximabrelated infusion reactions. Br J Dermatol 2008; 159:527-536.
52. Regueiro M, Schraut W, Baidoo L et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136:441-450.
53. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis. A pathological and clinical entity. JAMA 1932; 99:1323-1329.
54. Ferrante M, D'Haens G, Dewit O et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis 2010; 16:243-249.
55. Lofberg R, Louis EV, Reinisch W et al. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis 2012; 18:1-9.
56. Generini S, Giacomelli R, Fedi R et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63:1664-1669.
57. Brooklyn TN, Dunnill MG, Shetty A et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55:505-509.